BioAge Labs, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $2.8 million, a significant increase from $1.5 million in the same period last year. This 91% rise is attributed to heightened efforts under the company's collaboration agreement with Novartis Pharma AG. However, the company continues to face substantial operating losses, with a net loss of $22.3 million for the quarter, compared to a loss of $12.9 million in the first quarter of 2025, marking a 72% increase in losses year-over-year.
Operating expenses for BioAge Labs rose to $28.1 million, up from $17.9 million in the prior year, driven primarily by a substantial increase in research and development costs, which surged by 84% to $20.4 million. This increase is largely due to the completion of the Phase 1 clinical trial for the lead product candidate, BGE-102, and preparations for upcoming trials. General and administrative expenses also saw a rise, increasing by 14% to $7.7 million, reflecting higher personnel-related costs and legal fees.
In terms of financial position, BioAge Labs reported total assets of $397.7 million as of March 31, 2026, up from $294.9 million at the end of 2025. The increase in assets is primarily due to cash and cash equivalents, which rose to $241.8 million from $188.9 million, bolstered by a successful underwritten public offering that generated net proceeds of approximately $107.4 million in January 2026. The company’s accumulated deficit now stands at $355.7 million, indicating ongoing challenges in achieving profitability.
Operationally, BioAge Labs is advancing its clinical programs, particularly BGE-102, which targets cardiometabolic diseases. The company plans to initiate a Phase 2 trial for BGE-102 in mid-2026, focusing on patients with elevated cardiovascular risk. Additionally, BioAge is exploring other therapeutic areas, including ophthalmology, with plans for a proof-of-concept trial in diabetic macular edema expected to begin in mid-2026.
Looking ahead, BioAge Labs anticipates continued operating losses as it invests heavily in research and development. The company has sufficient cash reserves to fund operations through at least 2029, but it acknowledges the need for additional funding to support its growth strategy. The management remains focused on advancing its product candidates and exploring strategic partnerships to enhance its market position.
About BioAge Labs, Inc.
BioAge Labs, Inc. is a biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. Its platform leverages longitudinal human datasets and multi-omic profiling to identify novel targets like NLRP3 and apelin. The company develops oral, brain-penetrant small molecules and collaborates with major pharma firms to create innovative treatments for obesity and age-related conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.